生物活性

• 靶点	SGLT2 IC50:2.8nM

• 描述Ipragliflozin is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM, displaying little and NO potency for SGLT1/3/4/5/6.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT02528019	Effects of the DPP-4 Inhibitor... more >>s or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications Collapse <<	Phase 4	Unknown	August 2018	Japan ... more >> Kurume University Hospital Recruiting Kurume city, Japan, 830-0011 Contact: Nobuhiro Tahara, MD, PhD    +81-942-31-7580    ntahara@med.kurume-u.ac.jp    Contact: Sho-ichi Yamagishi, MD, PhD    +81-942-31-7562       Principal Investigator: Nobuhiro Tahara, MD, PhD Collapse <<
  NCT02284269	-	-	Active, not recruiting	-	-
  NCT02897219	Type 1 Diabetes Mellitus	Phase 3	Completed	-	Japan ... more >> Site JP00005 Aichi, Japan Site JP00028 Aichi, Japan Site JP00003 Chiba, Japan Site JP00013 Chiba, Japan Site JP00035 Chiba, Japan Site JP00022 Fukuoka, Japan Site JP00023 Fukuoka, Japan Site JP00031 Fukuoka, Japan Site JP00002 Gunma, Japan Site JP00011 Gunma, Japan Site JP00006 Hiroshima, Japan Site JP00033 Hokkaido, Japan Site JP00034 Hokkaido, Japan Site JP00021 Hyogo, Japan Site JP00009 Ibaraki, Japan Site JP00010 Ibaraki, Japan Site JP00004 Kanagawa, Japan Site JP00015 Kanagawa, Japan Site JP00016 Kanagawa, Japan Site JP00019 Mie, Japan Site JP00008 Nagasaki, Japan Site JP00024 Nagasaki, Japan Site JP00025 Nagasaki, Japan Site JP00032 Nagasaki, Japan Site JP00026 Niigata, Japan Site JP00020 Osaka, Japan Site JP00029 Osaka, Japan Site JP00036 Osaka, Japan Site JP00012 Saitama, Japan Site JP00017 Shizuoka, Japan Site JP00018 Shizuoka, Japan Site JP00001 Tochigi, Japan Site JP00030 Tokushima, Japan Site JP00014 Tokyo, Japan Site JP00027 Toyama, Japan Site JP00007 Yamaguchi, Japan Collapse <<

• 更多
• 参考文献

• [1] Tahara A, Kurosaki E, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55.

  [2] Imamura M, Nakanishi K, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012 May 15;20(10):3263-79.